CN113197864A - 一种酒石酸泰万菌素可溶性粉及其制备方法 - Google Patents

一种酒石酸泰万菌素可溶性粉及其制备方法 Download PDF

Info

Publication number
CN113197864A
CN113197864A CN202110496761.0A CN202110496761A CN113197864A CN 113197864 A CN113197864 A CN 113197864A CN 202110496761 A CN202110496761 A CN 202110496761A CN 113197864 A CN113197864 A CN 113197864A
Authority
CN
China
Prior art keywords
tylosin tartrate
soluble powder
beta
hydroxypropyl
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110496761.0A
Other languages
English (en)
Inventor
廖洪
武慧芳
袁方
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hfq Bio Technology Co ltd
Original Assignee
Jiangsu Hfq Bio Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hfq Bio Technology Co ltd filed Critical Jiangsu Hfq Bio Technology Co ltd
Priority to CN202110496761.0A priority Critical patent/CN113197864A/zh
Publication of CN113197864A publication Critical patent/CN113197864A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明公开一种酒石酸泰万菌素可溶性粉及其制备方法，主要由以下原料组成：酒石酸泰万菌素20‑50份，羟丙基‑β‑环糊精50‑80份，pH调节剂0.1‑1份和纯水。本发明工艺简单高效，制备出的酒石酸泰万菌素可溶性粉溶解度增加，稳定性提高，并能遮盖药物的不良气味，降低药物的刺激性，从而提高药物的生物利用度，增强药效、减轻副作用。通过控制喷雾干燥过程中物料粒径大小，提高了产品的流动性，更适合养殖终端的使用。

Description

一种酒石酸泰万菌素可溶性粉及其制备方法
技术领域
本发明涉及动物医药技术领域，具体涉及一种酒石酸泰万菌素可溶性粉及其制备方法。
背景技术
传统的酒石酸泰万菌素可溶性粉溶解度和稳定性较差，无法遮盖药物的不良气味，且具备一定的刺激性，从而增加了副作用，不利于养殖终端的使用。
发明内容
本发明的目的在于针对现有技术的缺陷和不足，提供一种酒石酸泰万菌素可溶性粉及其制备方法。
为实现上述目的，本发明采用的技术方案是：一种酒石酸泰万菌素可溶性粉，其创新点在于，主要由以下原料组成：酒石酸泰万菌素20-50份，羟丙基-β-环糊精50-80份，pH调节剂0.1-1份和纯水。
一种酒石酸泰万菌素可溶性粉的制备方法，其创新点在于，包括以下步骤：
S1、称取羟丙基-β-环糊精，常温溶解，与纯水比为1-2:5-8W/V，得到羟丙基-β-环糊***溶液；
S2、再按照比例称取酒石酸泰万菌素，溶于羟丙基-β-环糊***溶液中；
S3、常温包埋，搅拌1-2h，获得溶液；
S4、制得的溶液经喷雾干燥，得酒石酸泰万菌素可溶性粉，喷雾干燥过程中将酒石酸泰万菌素可溶性粉粒径控制在150-200μm。
本发明有益效果为：
本发明工艺简单高效，制备出的酒石酸泰万菌素可溶性粉溶解度增加，稳定性提高，并能遮盖药物的不良气味，降低药物的刺激性，从而提高药物的生物利用度，增强药效、减轻副作用。通过控制喷雾干燥过程中物料粒径大小，提高了产品的流动性，更适合养殖终端的使用。
具体实施方式
下面实施例对本发明作进一步的说明。
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合具体实施例，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施方式仅用以解释本发明，并不用于限定本发明。
实施例1
一种酒石酸泰万菌素可溶性粉的制备方法，包括以下步骤：
S1、称取羟丙基-β-环糊精50份，常温溶解，与纯水比为1:5W/V，得到羟丙基-β-环糊***溶液；
S2、再称取酒石酸泰万菌素20份，溶于羟丙基-β-环糊***溶液中；
S3、常温包埋，搅拌1h，获得溶液；
S4、制得的溶液经喷雾干燥，得酒石酸泰万菌素可溶性粉。喷雾干燥过程中将酒石酸泰万菌素可溶性粉粒径控制在150-200μm。
实施例2
一种酒石酸泰万菌素可溶性粉的制备方法，包括以下步骤：
S1、称取羟丙基-β-环糊精80份，常温溶解，与纯水比为2:8W/V，得到羟丙基-β-环糊***溶液；
S2、再称取酒石酸泰万菌素50份，溶于羟丙基-β-环糊***溶液中；
S3、常温包埋，搅拌2h，获得溶液；
S4、制得的溶液经喷雾干燥，得酒石酸泰万菌素可溶性粉。喷雾干燥过程中将酒石酸泰万菌素可溶性粉粒径控制在150-200μm。
实施例3
一种酒石酸泰万菌素可溶性粉的制备方法，包括以下步骤：
S1、称取羟丙基-β-环糊精70份，常温溶解，与纯水比为2:7W/V，得到羟丙基-β-环糊***溶液；
S2、再称取酒石酸泰万菌素40份，溶于羟丙基-β-环糊***溶液中；
S3、常温包埋，搅拌1.5h，获得溶液；
S4、制得的溶液经喷雾干燥，得酒石酸泰万菌素可溶性粉。喷雾干燥过程中将酒石酸泰万菌素可溶性粉粒径控制在150-200μm。
酒石酸泰万菌素改良前后溶解性对比：
(1)改良前后25％酒石酸泰万菌素溶解效果对比：
Figure BDA0003054724920000031
(2)改良后的25％酒石酸泰万菌素不同溶解浓度溶解效果对比：
Figure BDA0003054724920000032
从上表可以看出，本发明改良后的酒石酸泰万菌素在溶解性上优于传统改良强的酒石酸泰万菌素。
以上所述，仅用以说明本发明的技术方案而非限制，本领域普通技术人员对本发明的技术方案所做的其它修改或者等同替换，只要不脱离本发明技术方案的精神和范围，均应涵盖在本发明的权利要求范围当中。

Claims (2)

1.一种酒石酸泰万菌素可溶性粉，其特征在于，主要由以下原料组成：酒石酸泰万菌素20-50份，羟丙基-β-环糊精50-80份，pH调节剂0.1-1份和纯水。
2.一种根据权利要求1所述酒石酸泰万菌素可溶性粉的制备方法，其特征在于，包括以下步骤：
S1、称取羟丙基-β-环糊精，常温溶解，与纯水比为1-2:5-8W/V，得到羟丙基-β-环糊***溶液；
S2、再按照比例称取酒石酸泰万菌素，溶于羟丙基-β-环糊***溶液中；
S3、常温包埋，搅拌1-2h，获得溶液；
S4、制得的溶液经喷雾干燥，得酒石酸泰万菌素可溶性粉，喷雾干燥过程中将酒石酸泰万菌素可溶性粉粒径控制在150-200μm。
CN202110496761.0A 2021-05-07 2021-05-07 一种酒石酸泰万菌素可溶性粉及其制备方法 Pending CN113197864A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110496761.0A CN113197864A (zh) 2021-05-07 2021-05-07 一种酒石酸泰万菌素可溶性粉及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110496761.0A CN113197864A (zh) 2021-05-07 2021-05-07 一种酒石酸泰万菌素可溶性粉及其制备方法

Publications (1)

Publication Number Publication Date
CN113197864A true CN113197864A (zh) 2021-08-03

Family

ID=77029309

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110496761.0A Pending CN113197864A (zh) 2021-05-07 2021-05-07 一种酒石酸泰万菌素可溶性粉及其制备方法

Country Status (1)

Country Link
CN (1) CN113197864A (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114642641A (zh) * 2022-05-24 2022-06-21 山东国邦药业有限公司 一种酒石酸泰万菌素水溶性颗粒剂及其制备方法
CN118021765A (zh) * 2024-04-15 2024-05-14 中国农业科学院农业环境与可持续发展研究所 酒石酸泰万菌素纳米制剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107213470A (zh) * 2017-06-01 2017-09-29 中牧南京动物药业有限公司 酒石酸泰万菌素可溶性粉及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107213470A (zh) * 2017-06-01 2017-09-29 中牧南京动物药业有限公司 酒石酸泰万菌素可溶性粉及其制备方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114642641A (zh) * 2022-05-24 2022-06-21 山东国邦药业有限公司 一种酒石酸泰万菌素水溶性颗粒剂及其制备方法
CN114642641B (zh) * 2022-05-24 2022-07-26 山东国邦药业有限公司 一种酒石酸泰万菌素水溶性颗粒剂及其制备方法
CN118021765A (zh) * 2024-04-15 2024-05-14 中国农业科学院农业环境与可持续发展研究所 酒石酸泰万菌素纳米制剂及其制备方法

Similar Documents

Publication Publication Date Title
CN113197864A (zh) 一种酒石酸泰万菌素可溶性粉及其制备方法
CN106106522B (zh) 一种纳米氧化锌-载银壳聚糖复合抗菌剂及其制备方法
CN112624659B (zh) 一种复合型植物蛋白发泡剂及其制备方法
CN100448371C (zh) 纳米微胶囊牛肉香精及其制备方法
CN105147620A (zh) 一种硫氰酸红霉素可溶性粉及其制备方法
CN103539868A (zh) 一种制备羧甲基壳聚糖的方法
CN104857517A (zh) 一种恩杂鲁胺软胶囊及其制备方法
CN112190551A (zh) 一种氟苯尼考可溶性粉及其制备方法
CN103829119A (zh) 一种蜂蜜粉的配方及其加工工艺
US20220105045A1 (en) Pullulan empty hard capsule and preparation method therefor
CN112979503A (zh) 一种卡巴匹林钙的制备方法
CN106176769B (zh) 兽用长效土霉素注射液及其制备方法
CN107057250A (zh) 一种环保pvc装饰材料
CN108853024B (zh) 一种硫酸黏菌素可溶性粉及其制备方法
CN115300461A (zh) 一种氟苯尼考可溶性粉及其制备方法
CN115844849A (zh) 纤维素植物软胶囊及其制备方法
CN104546788B (zh) 一种辛伐他汀片的制备方法
CN113694847A (zh) 一种维生素b12微胶囊片剂的制备方法
CN113425686A (zh) 地美硝唑可溶性粉及其制备方法
CN107033300A (zh) 一种具有高效保水性能的农林保水剂及制作方法
CN107184545A (zh) 一种魔芋葡甘聚糖眼用凝胶剂及其制备方法
CN106727618A (zh) 复方磺胺甲噁唑口服混悬剂及其制备方法
CN106700092A (zh) 一种微波辅助制备富里酸银的方法
CN109457515A (zh) 一种毛棉织物数码印花糊料的制备方法
CN113563492B (zh) 一种分子型低酯果胶铜及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210803

RJ01 Rejection of invention patent application after publication